The SAGE Handbook of Healthcare, 1st Edition

  • Published By: SAGE
  • ISBN-10: 1847877001
  • ISBN-13: 9781847877000
  • Grade Level Range: College Freshman - College Senior
  • eBook
  • Original Copyright 2008 | Published/Released May 2008
  • This publication's content originally published in print form: 2008

  • Price:  Sign in for price



With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today's healthcare industry.

The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace.

The Handbook focuses on the aspects of paramount importance in the healthcare sector:

  • Pharmacoeconomics
  • Pharmacogenomics
  • Therapeutics
  • Diagnostics

Areas covered include:

  • The role of nanotechnology, genomics and cell therapy in medicine
  • Diagnostics; Biomarkers and technological advances
  • Case studies in oncology and cardiovascular and CNS therapeutics

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
1: Pharmacoeconomics.
2: Medicare Part D: An Outlook.
3: Changes in US Oncology Drug Reimbursement: Medicare Sets the Pace.
4: Prospective Payment Systems: Opportunities and Threats for the Pharmaceutical Industry.
5: Off-label Prescribing: Overcoming the Reimbursement Barrier.
6: Pricing and Reimbursement Issues in Neurology.
7: Authorized Generics: Look Before You Leap.
8: Pharmaceutical Pricing and Reimbursement in Canada.
9: Contrasting European and US Patent Laws: Issues for the Pharmaceutical Industry.
10: The Changing Face of European Drug Registration.
11: The Impact of Reference Pricing in Europe.
12: Pharmaceutical Pricing, Reimbursement, and Prescribing in the United Kingdom.
13: Pharmaceutical Pricing, Reimbursement, and Prescribing in Italy.
14: Pharmaceutical Pricing, Reimbursement, and Prescribing in Spain.
15: The Impact of German Reference Pricing on Statins.
16: Opportunities and Challenges in the Japanese Market for Cancer Therapies.
17: Cancer Therapies Face Increasing Reimbursement Pressures in Europe and Japan.
18: The Pharmaceutical Pricing and Reimbursement Environment in China.
19: Will Point of Care Come of Age by 2010?.
20: Pharmacogenomics.
21: Has Genomics Failed to Deliver?.
22: The Role of Pharmacogenomics in Personalized Medicine.
23: Cell Therapy: A Decade of Opportunity.
24: Nanotechnology in Medicine: Its Time Has Come.
25: Clinical Proteomics: An Engine for In vitro Diagnostics Growth?.
26: Therapeutics.
27: Oncology.
28: Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers.
29: Antitumor Biologies: Strategies for Success in An Expanding Market.
30: Outlook for Cancer Vaccine Development.
31: Advances Imminent in Antiangiogenesis Therapeutics.
32: Discoveries and Challenges in Early-Stage Apoptosis Drug Development.
33: Chronic Lymphocytic Leukemia: Monoclonal Antibodies Will Drive Steady Growth.
34: CNS.
35: Opportunities in the Pharmacotherapy of Addiction.
36: Immunology.
37: Prevention of Organ Transplant Rejection: Current Therapies and Novel Strategies.
38: Cardiovascular.
39: Cardiovascular Drugs and Devices Market: Some Successes and Setbacks in Recent Years.
40: Renin Inhibitors: A Novel Approach to Hypertension.
41: Future of VLA-4 Antagonist Drugs and Implications for the Regulatory Process.
42: Impact of Inhaled Insulin on the Insulin Market.
43: Impact of the PROactive Study on the Treatment of Type 2 Diabetes.
44: Diagnostics.
45: Integrating Diagnostics and Therapeutics for Targeted Therapies – Part 1: Optimizing the Comarketing Plan.
46: Integrating Diagnostics and Therapeutics for Targeted Therapies – Part 2: The Importance of Calculating the Return on Investment.
47: Emerging Diagnostic Markers in Alzheimer's Disease.
48: How Are Translational Medicine Biomarkers Impacting Industry?.
49: Unlocking the Potential of Biomarkers in Targeted Oncology.
50: From Bioterrorism to Predictive Medicine: New Applications of Salivary Diagnostics.